| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5889994 | Bone | 2015 | 9 Pages |
â¢Molecular switches of osteoblast and adipocyte are ideal “druggable” targets for enhancing bone formation.â¢The non-canonical Notch signaling molecule Dlk1/Pref-1 is a novel inhibitor of bone mass.â¢Wnt signaling receptor Lrp5 regulates the commitment of BMSCs into osteoblasts versus adipocytes.â¢Regulating BMSC differentiation by kinase inhibitors is a novel approach for enhancing bone formation.
Skeletal (marrow stromal) stem cells (BMSCs) are a group of multipotent cells that reside in the bone marrow stroma and can differentiate into osteoblasts, chondrocytes and adipocytes. Studying signaling pathways that regulate BMSC differentiation into osteoblastic cells is a strategy for identifying druggable targets for enhancing bone formation. This review will discuss the functions and the molecular mechanisms of action on osteoblast differentiation and bone formation; of a number of recently identified regulatory molecules: the non-canonical Notch signaling molecule Delta-like 1/preadipocyte factor 1 (Dlk1/Pref-1), the Wnt co-receptor Lrp5 and intracellular kinases. This article is part of a Special Issue entitled: Stem Cells and Bone.
